EDUCATION > Guidelines & Policies > Guidelines > Incontinence

Incontinence

Download the unabridged version of this guideline [pdf]

Guideline for the Surgical Management of Female Stress Urinary Incontinence: Update (2009)

Panel Members:
Rodney A. Appell, MD, Chair; Roger R. Dmochowski, MD, Facilitator; Jerry M. Blaivas, MD; E. Ann Gormley, MD; Mickey M. Karram, MD; Saad Juma, MD; Deborah J. Lightner, MD; Karl M. Luber, MD; Eric Scott Rovner, MD; David R. Staskin, MD; J. Christian Winters, MD

Introduction

Stress urinary incontinence (SUI) has a significant impact on the quality of life for many women, although estimates of prevalence vary widely due to inconsistencies in the definitions of SUI and differences in populations studied.1 A large meta–analysis reported an estimated prevalence for urinary incontinence of 30% in women aged 30 to 60 years, with approximately half of the cases attributed to SUI;2 another study reported the prevalence of SUI was 5% to 30% in European women.3 Many women in the United States (U.S.) elect to have a surgical procedure for management of their SUI symptoms each year. The first Female Stress Urinary Incontinence Clinical Guidelines Panel reviewed literature available up to January 1994 and published its report in 1997.4 Since that time, a new body of literature has emerged on primarily novel surgical interventions for the treatment of SUI. For these reasons, the American Urological Association (AUA) has elected to update the initial report on the Surgical Management of Stress Urinary Incontinence. The literature search used in this analysis had a conclusion date of June 2005; it is recognized that this guideline will likely change in response to new information and further developments in the field.

In the 1997 guideline, the index patient was an otherwise healthy female patient with SUI without significant pelvic organ prolapse. It has become apparent since the prior guideline that many women with SUI also have pelvic organ prolapse and that these two issues may be addressed concurrently. Therefore, in constructing this guideline update, the index patient is defined as an otherwise healthy female patient who has elected surgical therapy for the correction of SUI as in the previous guideline. An additional index patient defined by the panel is an otherwise healthy female patient with SUI and prolapse who elects to have treatment of her SUI along with surgical correction of prolapse. The current Female Stress Urinary Incontinence Guideline Update Panel (the Panel) was selected by the Panel chair and approved by the Practice Guidelines Committee (PGC) of the AUA. The Panel members are representative of different medical specialties and geographic regions of the U.S. and are from both academic and private institutions.

This report describes an analysis of efficacy and safety outcomes for surgical procedures for use in treatment of SUI and provides a guideline based on review of these data and/or panel consensus. It also offers a discussion about the diagnostic evaluation of the index patient and recommendations for outcomes reporting and future research.

Definitions

Stress urinary incontinence is a symptom that refers to leakage of urine during events that result in increased abdominal pressure such as sneezing, coughing, physical exercise, lifting, bending and even changing positions. There are two principle causes of this symptom – SUI and the rarer stress–induced detrusor overactivity (involuntary detrusor contractions that are caused by sudden increases in abdominal pressure). The distinction between these two can be determined by (in order of increasing specificity) patient history, physical examination (e.g., urinary loss after a stress event) and urodynamic studies. For the purposes of this guideline, it is assumed that patients in the extracted studies had surgical management of SUI.

Urgency refers to a sudden, compelling desire to pass urine which is difficult to defer5 or a strong need to pass urine for fear of leakage.6 Urge urinary incontinence is defined as involuntary leakage accompanied by or immediately preceded by urgency.5 Mixed incontinence refers to SUI that occurs in combination with urge urinary incontinence.

Index patient

The index patient is defined as an otherwise healthy female patient who has elected surgical therapy for the correction of SUI as in the previous guideline. An additional index patient defined by the panel is an otherwise healthy female patient with SUI and pelvic organ prolapse who elects to have treatment of her SUI along with surgical correction of pelvic organ prolapse. Either index patient may be untreated or previously surgically–treated and may have urethral hypermobility and/or intrinsic sphincter deficiency. Urethral hypermobility was defined by the author; no uniform definition was used.

Methodology

This guideline included analysis of those relevant factors (perceived risks and outcomes of the interventions, patient preferences and relative priorities of the interventions given limited health care resources) used to choose among alternative treatment interventions.7 The peer–reviewed medical literature was meta–analyzed to estimate outcomes of treatment modalities, and Panel members themselves served as proxies for patients in considering preferences. The steps taken to develop this guideline, further detailed in Chapter 2, included problem definition, literature search, data extraction, systematic evidence combination, guideline generation, approval and dissemination. The Panel did not review needle suspensions or anterior colporrhaphy in developing this guideline update. Since development of the 1997 guideline, very limited new data has been published addressing these procedures, and there is a lack of current use or interest in them as well. Though these operations may still be performed in isolated circumstances by some surgeons, the Panel believes that they are largely of historical interest only and no longer considers these procedures contemporary treatments for SUI.

Problem Definition

This guideline update was based on the original AUA Guideline on the Surgical Management of Female Stress Urinary Incontinence published in 1997 using a similar methodology. The analysis was likewise limited to surgical treatments but included new procedures and those considered the most efficacious as determined by the previous analysis. Unlike the 1997 guideline, outcomes of surgical therapies for prolapse were also included.

Surgical efficacy was defined in three parts: 1) the resolution and lack of recurrence of SUI and urgency; 2) the resolution of prolapse and the lack of recurrence or new onset of prolapse; and 3) the incidence and severity of adverse events of these treatments. Urgency (resolution and de novo) was included as an efficacy outcome due to its significant impact on patient quality of life. The treatments included in the analysis were retropubic suspensions, slings, injection therapy and artificial sphincters; the analysis excluded those procedures not generally available in the U.S. or not expected to be approved at the time of publication. Anterior repairs for prolapse reduction in conjunction with other surgical treatments for incontinence were included as prolapse surgeries. Procedures used to correct prolapse included hysterectomy in conjunction with or as a component of surgical treatment of SUI and site–specific repairs.

Literature Search and Data Extraction

A database was generated that included articles retrieved for the previous guideline and those resulting from a series of four MEDLINE® searches beginning in December 2002 and concluding in June 2005. The searches were limited to papers involving human subjects and published in the English language on or after 1990 which included the MeSH term "female." The MeSH headings used were "urinary incontinence, stress," "stress incontinence" and "urinary incontinence" in any field. A total of 7,111 citations and abstracts were reviewed for relevance by the panel chairs, of which 1,302 citations entered the extraction process. Panel members extracted data from the articles which were then entered into a Microsoft Access® (Microsoft, Redmond, WA) database. In person and via conference calls, the Panel collectively reviewed the extracted data. A total of 436 articles were suitable for inclusion in the meta–analysis; an additional 155 articles were deemed suitable only for their complications data due to an insufficient follow–up duration for the efficacy outcomes analysis.

Evidence Combination

To generate outcomes tables, estimates of the probabilities and/or magnitudes of the outcomes are required for each intervention. Ideally, these come from a synthesis or combination of the evidence. Combination can be performed in a variety of ways depending on the nature and quality of the evidence. For this guideline, the panel used the confidence profile method,8, 9 which provides methods for meta–analyzing data from studies that are not randomized controlled trials (RCTs). Meta–analysis was performed using the Fast*Pro software to combine individual arms from controlled trials and clinical series where similar patients were similarly treated. Although a number of RCTs were found through the literature search, there were insufficient numbers on any one topic to warrant an independent meta–analysis of RCTs. The results of certain trials are discussed where relevant. Frequently, published series used in a combined analysis showed very divergent results implying site–to–site variations, variability in patient populations, in the performance of the intervention, the skill of the surgeon or normal statistical variation. Given these differences, a random–effects, or hierarchical, model was used to combine the studies.

Patient Groups

While stratifying outcomes based on patient characteristics such as type of incontinence, previous treatment(s), presence of prolapse, prior pregnancy and severity of incontinence would be most instructive, in most cases the outcomes data were not fully or consistently identified by these criteria. Therefore, analysis was limited to two patient groups; one in which no patient received concomitant surgical treatment for prolapse (comparable to the previous guideline) and another in which some or all patients received concomitant treatment for prolapse. Very few published studies included all of the SUI patients receiving concomitant prolapse treatment, therefore, the analysis was based mainly on data from studies that included some patients with prolapse treatment. This did not permit a clear distinction to be made between these groups in the analysis. An attempt to stratify the outcomes of SUI surgical interventions by the presence of prolapse was thwarted by insufficient data since few published studies stratified results in this manner.

Efficacy Analysis

The efficacy outcomes analyzed included two levels of continence: cured/dry and cured/dry/improved; these are reported percentages and credible intervals (Bayesian confidence intervals [CIs]). Allocation to the previously mentioned categories was determined by author definition of continence. For the analysis of postoperative urgency, patients were divided into three categories: without pre–existing urgency, with pre–existing urgency, and unknown or uncertain pre–existing urgency. Postoperative urgency categories included urge incontinence, urge symptoms and unspecified. Again, the results are reported as the percent of the relevant patient group having each outcome. Abbreviated tables summarizing the cured/dry and resolution or urge incontinence for the time interval of 12–23 months for patients with or without concurrent prolapse treatment are provided with this document (see Tables 1–3); for a complete set of data tables see Appendices A7–A16.

Complications

Complications were analyzed similarly to the efficacy outcomes. However, because of the wide variety of ways authors name and describe complications, the panel attempted to group complications together that represented the same or related outcomes. As discussed in Chapter 2, this could result in some inaccuracies in the resultant estimates. Appendix A–17 shows how the panel grouped outcomes. Certain complication outcomes such as pain and de novo urgency were tabulated as defined by the author, and no further analysis was performed based upon the limitations of data reporting. After grouping the complications for analysis, the grouped complications were then put into general categories for display and discussion. Outcomes tables were developed for each group of complications. Separate tables were again created for patients with and without prolapse treatment. The format of the tables is the same as the efficacy tables. An abbreviated table summarizing retention data for patients with or without concurrent prolapse treatment is provided with this document (see Table 4); for a complete set of data tables see Appendices A7–A16.

Guideline Generation and Approvals

After the evidence was combined and outcome tables were produced, the Panel reviewed the results and identified anomalies, updated the outcomes tables based on the problems identified, and based on evidence from the outcome tables and expert opinion, the Panel drafted the treatment guideline. Based on 24 peer reviewer comments, the Panel revised the document. The guideline was submitted for approval to the PGC of the AUA and the Board of Directors for final approval.

As in the previous guideline, the present statements are graded with respect to the degree of flexibility in application. Although the terminology has changed slightly, the current three levels are essentially the same as in the previous guideline. A "standard" has the least flexibility as a treatment policy. A "recommendation" has significantly more flexibility, and an "option" is even more flexible. These terms are defined as follows:

1. Standard: A guideline statement is a standard if (1) the health outcomes of the alternative interventions are sufficiently well known to permit meaningful decisions, and (2) there is virtual unanimity about which intervention is preferred.

2. Recommendation: A guideline statement is a recommendation if (1) the health outcomes of the alternative interventions are sufficiently well known to permit meaningful decisions, and (2) an appreciable, but not unanimous majority agrees on which intervention is preferred.

3. Option: A guideline statement is an option if (1) the health outcomes of the interventions are not sufficiently well known to permit meaningful decisions, or (2) preferences are unknown or equivocal.

Dissemination

The guideline is published on the web site for the AUA and can be found at http://www.auanet.org. A version of Chapter 1 will be published in the Journal of Urology.

Diagnostic Evaluation of the Index Patient

The purpose of diagnostic evaluation is three–fold: 1) to document and characterize SUI; 2) to assess differential diagnosis and comorbidities; and 3) to prognosticate and aid in the selection of treatment.

To confirm the diagnosis and characterize SUI

Stress urinary incontinence may be characterized by the following:

On the basis of a focused history and physical examination with a comfortably full bladder, the diagnosis of SUI is fairly straightforward in the index patient. The sine–qua–non for a definitive diagnosis is for the examiner to witness involuntary urine loss from the urethral meatus coincident with increased abdominal pressure (positive stress test) such as those occurring during coughing and straining; a standing position may facilitate the diagnosis. Once the increase in abdominal pressure has subsided, flow through the urethra should subside. Rarely, one may witness urine loss after increases in intra–abdominal pressure. In this scenario, one should suspect that the incontinence is, at least in part, due to an abnormal detrusor contraction (stress– induced detrusor overactivity).

To assess differential diagnosis and comorbidities

The differential diagnosis of stress incontinence includes detrusor overactivity, low bladder compliance, overflow incontinence, stress–induced detrusor overactivity, urethral diverticulum, urinary fistula and ectopic ureter. Overflow incontinence is a clinical diagnosis, whereas detrusor overactivity, low bladder compliance, and stress–induced detrusor overactivity are essentially urodynamic diagnoses while urethral diverticulum and urinary fistula can be sometimes be confirmed on the basis of history and exam but may in some instances require urinary tract imaging or other procedures for confirmation. Various imaging techniques for urethral diverticula may be used. Urinary fistula and ectopic ureter may be diagnosed by examination, cystoscopy and upper and lower urinary tract imaging.

Certain comorbidities relating to coexisting conditions might affect the outcome of treatment and influence surgical technique and the specifics of patient counseling. For example, a patient with mixed and stress incontinence who has a large post–void residual volume and impaired detrusor contractility might be counseled that her urge symptoms are more likely than usual to persist and that urinary retention is more likely. Further, the technique of surgery might be tailored such that a mid urethral, rather than bladder neck, sling is performed and it might be placed a bit looser than otherwise. These comorbidities include:

To aid in prognosis and selection of treatment

There are few facts and many opinions about predicting the outcome of surgery based on the comorbidities described above, though few would disagree that operations for SUI should be confined to those who actually have demonstrable SUI, including occult SUI demonstrable only after reduction of pelvic organ prolapse. There is no standardized way to reduce a prolapse to unmask stress incontinence, and this patient falls outside the index patient identified by the panel. Nevertheless, an understanding of the specific comorbidities allows for individualized treatment planning, for informed consent and for the surgeon's estimate of a successful outcome and the potential occurrence of complications such as incomplete bladder emptying, persistent or de novo urgency/urge incontinence and recurrent sphincter incontinence. Urodynamic evaluation may be of assistance in elucidating complex presentations of incontinence.

Diagnostic Guidelines for the Index Patient

Amendments to 1997 Standards, Recommendations and Options are indicated (words that are in italics denote changes from the 1997 guideline document to improve clarity).

Standard: The evaluation of the index patient should include the following components:

[Based on Panel consensus]

Recommendation: Elements of the history should include the following:

[Based on Panel consensus]

Recommendation: Additional diagnostic studies can be performed to assess the integrity and function of the lower urinary tract.

[Based on Panel consensus]

Recommendation: Indications for further testing include the following:

[Based on Panel consensus]

The need for further evaluation of any given patient depends on a number of other factors including the degree of certainty and comfort that the physician has about the diagnosis, the impact that further studies will have on diagnosis, treatment options and treatment risks and likely outcomes as well as the desire and willingness of the patient to undergo further studies.

Therapeutic Options

Nonsurgical Treatment

Management of SUI includes the option of nonsurgical therapies. The Panel did not review nonsurgical therapies because they are outside the scope of this report.

Surgical Treatment

The outcomes analyzed fell into two general categories: efficacy outcomes and complications. The results of the analysis are provided under each treatment below. For a more detailed discussion of the outcomes, see Chapter 3. Comparative results of the meta–analysis of efficacy and complications are shown in the tables and graphs in Chapter 3.

Outcomes Analysis

Efficacy

The primary efficacy outcome was the resolution of stress incontinence as measured two ways— patients who were completely dry (cured/dry) or patients who showed improvement (cured/dry/improved). The cured/dry/improved measure may include patients who were completely dry. Secondary efficacy outcomes dealt with changes in urgency as described in the methodology section above. Data were accepted as reported except when described in terms that conflicted with the definition in the methodology. For example, if a study reported any patients with minimal persistent incontinence as cured, these data were included only in the cured/dry/improved category.

Outcomes were analyzed separately based on whether the continence evaluation was subjective or objective; only results that were clearly based on subjective or objective criteria were included in their respective analyses. An additional category was created (defined as "any" method of evaluation) to include all studies irrespective of the method of assessment used. For studies reporting both subjective and objective results, the subjective results for the study were included in the "any" category.

Outcomes also were analyzed separately according to the postsurgical interval of the final assessment of continence, with a minimum period of follow–up of 12 months. Three intervals were analyzed: 12 to 23 months, 24 to 47 months and greater than 48 months. If a study reported data at multiple times during one of these intervals, the time point closest to 18 months, 36 months and 60 months were used for the three time ranges, respectively.

Complications

In order to facilitate the analysis of complications for the various SUI surgical procedures and because of the lack of standardized complications nomenclature in the literature the Panel grouped the reported complications into the following classes:

  • Urinary retention
  • Gastrointestinal
  • Infectious
  • Perioperative genitourinary
  • Vascular
  • General medical
  • Delayed genitourinary
  • Neurological
  • Death

Details of these groups are described in Chapter 3. Appendix A–17 lists the specific complications that were included in each of the above classes. Subjective complications (pain, sexual dysfunction, and voiding dysfunction) were also included as a separate category.

Important complications for specific treatments are discussed below under the relevant treatment.

Surgical Treatments Analyzed – Descriptions and Outcomes

The surgical treatments analyzed fell into four categories: retropubic suspensions, slings, injectable agents and artificial urinary sphincters (AUS). Within each class, modifications of these treatments were analyzed where appropriate. For some categories, only minimal data were available. As noted in the methods section, definitions of cured, dry and improved were those of the authors.

In this section, brief descriptive results are provided for outcomes. The complete results are provided in Chapter 3 and Appendices A7–A16.

Retropubic Suspensions

Although the techniques for performing retropubic suspensions were essentially unchanged since the 1997 Guideline, the Panel elected to determine if there were any new studies since that analysis that would result in significantly different outcomes. Data from three categories of retropubic suspensions were analyzed: 1) open suspensions regardless of type (including Burch suspensions); 2) open Burch suspensions alone; and 3) laparoscopic suspensions.

The Panel's meta–analysis estimated cured/dry rates at 12 to 23 months based on 1,085 patients for open suspensions with no concomitant prolapse treatment to be 82% (CI: 74%–87%) while cured/dry rates for laparoscopic suspensions were 69% (368 patients; CI: 52%–84%) (Table 1). At 24 to 47 months, the cured/dry rates were similar among all procedures, ranging from 74% to 76%. At 48 months or longer, cured/dry rates for all open procedures were 73%. No data were available for laparoscopic procedures. These rates are similar to those reported for retropubic suspensions in the previous Guideline, in which estimated cured/dry rates were 84% at all time points.4

The meta–analysis estimate of postoperative urge incontinence was 14% from data from 186 patients (CI: 6%–25%) with pre–existing urge incontinence when treated with open retropubic suspensions, while de novo urge incontinence and "unspecified" urge incontinence was estimated in 8% (713 patients; CI: 5%–12%) and 41% of patients (305 patients; CI: 30%– 54%), respectively (Table 3). Of patients undergoing laparoscopic retropubic suspensions, the meta–analytic results indicate that an estimated 5% of patients (CI: 1%–14%) will experience de novo urge incontinence and approximately 6% (CI: 1%–14%) will have "unspecified" urge incontinence. There were few data available for laparoscopic retropubic suspensions or for longer term outcomes of open retropubic suspensions (for longer term outcomes on urge incontinence, see Chapter 3). Based on 1,154 patients in 18 studies, retention could occur in 3% to 4% of patients (Table 4). The most common complications and estimated rates of occurrence for open retropubic suspensions determined in the meta–analysis (see Chapter 3) were febrile complications (8%), urinary tract infection (13%), bladder injury (4%) and voiding dysfunction (9%). Laparoscopic suspensions appeared to have a lower overall risk of febrile complications (0% reported) and urinary tract infection (2%), although these estimates were based on limited data. Ureteral injury was estimated to occur in 4–11% of patients receiving laparoscopic retropubic suspensions (see later discussion in Chapter 3), but only 1% of patients receiving open suspensions. Again, these estimates were based on a very small number of patients.

For patients with concomitant prolapse treatment, the estimated cured/dry rates for open retropubic suspensions, Burch suspensions and laparoscopic suspensions were all 88% at 12 to23 months and 83% to 85% at 24 to 47 months (Table 2). The cured/dry rate was estimated to be 67% (1,072 patients; CI: 56%–76%) for all open retropubic suspensions at 48 months or longer, and data were insufficient for an approximation of efficacy for laparoscopic therapy at 48 months or longer. The postoperative urge incontinence rate was based on 143 patients with pre–existing urge incontinence who were treated with open retropubic suspensions with concurrent prolapse repair; the rate of occurrence was approximately 22% (CI: 4%–56%). Further, the analysis estimates 14% of patients (457 patients; CI: 8%–21%) may experience de novo urge incontinence and 13% of patients (256 patients; CI: 7%–22%) may report "unspecified" urge incontinence (Table 3). By comparison, the results estimate that 11% of patients treated with laparoscopic suspensions will have de novo urge incontinence (344 patients; CI: 6%–17%); data were unavailable or insufficient for the other urge incontinent outcomes with laparoscopic retropubic suspensions (for longer term outcomes on urge incontinence, see Chapter 3). Retention was estimated in 1% to 2% of patients (Table 4).

Slings

Autologous Fascial Slings

Efficacy data were available for a variety of types of autologous fascial slings, including suprapubic slings with bone anchors, autologous vaginal wall slings with or without bone anchors and the general category of autologous fascial slings without bone anchors (detailed outcomes for the different types of autologous fascial slings are provided in Chapter 3).

Most of the available studies described patients treated with autologous slings without bone anchors. For patients without concurrent prolapse treatment, the estimated cured/dry rates ranged between 90% at 12 to 23 months and 82% at 48 months or longer (Table 1). The Panel's meta–analysis estimated rates of postsurgical urge incontinence were 33% in patients with pre– existing urge incontinence and de novo urge incontinence in 9% of patients without pre–existing urge incontinence (Table 3). The estimated rate of retention was 8% (Table 4). Complications estimates for autologous fascial slings without bone anchors were generally infrequent and included urinary tract infection (11%), bladder injury (4%) and wound complications (8%). There were also a few studies published between 2001 and 2003 reporting data on a small number of patients who received autologous fascial vaginal wall slings with or without bone anchors. Complete data are provided in Chapter 3.

For patients treated with autologous slings without bone anchors and a concurrent prolapse treatment, cured/dry rates ranged from 85% to 92%, although these estimates were based on a very small number of patients (Table 2). Based on the results of the meta–analysis, approximately 10% of patients could experience de novo urge incontinence, and an estimated 5% of patients will be subject to retention (Table 3).

Cadaveric Slings

Cadaveric slings came into wide use following a report by Handa et al.,10 and other authors have since reported favorable results using this procedure.11, 12 However, the long–term durability of these procedures has been questioned,13, 14 with reports of graft failure15, 16 and declining success rates over time17, 18 (for a more complete discussion on the use of cadaveric slings, see Chapter 3). The use of these materials has dramatically declined over time as a result of these concerns, thus severely limiting data available for analysis.

Based on the limited data available for analysis, the estimated cured/dry rate for patients undergoing cadaveric slings without bone anchors and no concomitant prolapse treatment was 74% at 12 to 23 months and 80% at 24 to 47 months (Table 1). There were no data for longer term efficacy (48 months or longer) for cadaveric slings, and few studies reported data on retention, urge incontinence or complications.

For patients with concomitant prolapse treatment, the Panel's meta–analysis estimates of cure/dry rates were 82% (234 patients CI: 77%–86%) at 12 to 23 months using a cadaveric sling with bone anchors, whereas the rate was 58% based on patients from three studies totaling 133 patients (CI: 36%–78%) where bone anchors were not utilized (Table 2). Despite the fact that these confidence intervals barely overlap, the consensus of the Panel is that these represent statistical aberrations inherent in evidence combination and are likely not representative of a true difference in outcomes. There were no data for bone–anchored slings beyond two years. At 24 to 47 months, for patients undergoing a cadaveric sling procedure without bone anchors in addition to prolapse treatment, the cured/dry rate was 64%, and at > 48 months based on 13 patients, only an estimated 31% receiving a cadaveric sling without bone anchor will be cured/dry.

Little is known about the graft–host relationship and possible mechanisms of graft degradation for cadaveric materials. In addition, processing and storage of these materials is variable, which could account for the disparity of results as reflected by the wide CIs in our analysis. There were insufficient data to assess the long–term efficacy of these procedures, with very few studies reporting results at 48 months or longer. Furthermore, the risks of disease transmission with these materials remain unknown. Traces of genetic material have been isolated from commercially available cadaveric sling materials19 although there have been no reports of disease transmission related to cadaveric grafts in the urologic literature.

There were few complications reported in the literature for procedures using cadaveric sling materials. Vaginal extrusion was reported in one study,20 but erosion of cadaveric materials into the urinary tract was not identified in this meta–analysis. Other reported complications were similar to other procedures for the surgical correction of SUI. When these materials have been used with concomitant prolapse repair, complications such as infection and graft extrusion have been reported.21

Synthetic Slings

Efficacy data were available for synthetic slings placed at the bladder neck and synthetic slings placed at the midurethra. Outcomes are discussed separately for each of these procedures.

Synthetic Slings at the Bladder Neck

Efficacy data were available for synthetic slings at the bladder neck with or without bone anchors; most of the data came from studies involving synthetic slings without bone anchors. With this procedure, the estimated cured/dry rate based on 349 patients in nine studies without prolapse treatment was 73% (CI: 64%–80%) at 24 to 47 months; longer term data were not available (Table 1). De novo urgency was approximated at 12% of patients (132 patients; CI: 6%–20%) at 12 to 23 months; there were limited data on other urge incontinence outcomes (Table 3). The retention rate was an estimated 9% (360 patients; CI: 5%–15%) (Table 4). The most common complications occurring with synthetic slings at the bladder neck without bone anchors (provided in Chapter 3) were urinary tract infection (10%) and erosion/extrusion (5% for urethral/bladder, 8% for vaginal and 17% for unknown). However, because only studies that report a given complication were included in the analysis and many of these studies were small case series, these percentages may represent an overestimation of the risk of these complications. Despite these limitations, these data suggest an increased probability of urinary tract erosion following synthetic slings placed at the bladder neck.

For those treated with synthetic slings at the bladder neck with concurrent prolapse treatment, the meta–analysis estimated cured/dry rates of 73% to 75% at 24 months and longer (Table 2). Estimates of postoperative urge incontinence based on 119 patients with pre–existing urge incontinence in three studies was 29% (CI: 16%–46%), and estimates suggested that only 15% of patients (150 patients; CI: 5%–31%) will experience de novo urge incontinence (Table 3). The estimated retention rate was 10% (422 patients; CI: 5%–18%) (Table 4).

Synthetic Slings at the Midurethra

Since the publication of the 1997 guideline, there has been a proliferation of new modifications to the pubovaginal sling that have largely replaced the retropubic suspension and the autologous sling as the primary procedures for SUI. In these procedures the synthetic sling is placed at the midurethra as opposed to the bladder neck. These procedures are performed using one of two techniques–transvaginal/retropubic or transobturator. In the retropubic technique, trocars or long needles are passed at the midurethra through the retropubic space from the vagina to the abdomen or from the abdomen to the vagina. In the transobturator technique, the slings are passed with a curved trocar from the vagina behind the ischium (inside–out) or from the ischium to the vagina (outside–in). At the time of this analysis, data on the transobturator technique was limited, with insufficient numbers of patients having long–term follow–up to reach any conclusions regarding efficacy (see final section of this document for further discussion of these procedures).

For the transvaginal/retropubic technique, the Panel's meta–analysis estimated cured/dry rates in patients without prolapse treatment ranging from 81% to 84% at all time points (Table 1), which is comparable to the medium–term results for the Burch suspensions and autologous fascial slings. De novo urge incontinence was projected in 6% of patients (323 patients; CI: 3%– 10%) (Table 3) while retention estimates were 3% of patients (2119 patients; CI: 2%–4%) (Table 4); insufficient data were available for an estimate of resolution of pre–existing urgency, with only 1 group of 25 patients providing data. Complication rates (see Chapter 3) included bladder injury as defined by the study authors (6%), urinary tract infection (11%) and extrusions (7% for vaginal extrusions and 1% for unknown). Wound complications were also reported in the literature. Thirteen case reports identified the complications of urethral or bladder erosion of mesh into the urinary tract which occurred in over half of a cohort of 33 patients. Unfortunately, the probability of urinary tract erosion was unable to be calculated precisely from the database as all of these were reports of individual cases or small case series which would result in an overestimation of the risk of these complications. Similar efficacy results were found for those treated with midurethral synthetic slings with concurrent prolapse treatment.

Mesh in pelvic floor surgery**:

**The FDA issued an updated warning in July 2011 regarding the use of vaginal mesh. Please read the alert on the cover of this guideline.

Recently, the U.S. Food and Drug Administration (FDA) released a warning position statement concerning the use of mesh materials in stress incontinence surgery and pelvic organ prolapse surgery. They noted over 1,000 reported complications of vaginal and urinary erosion as well as bowel and vascular injuries. This data has been extracted from the FDA Manufacturer and User Facility Device Experience Database (MAUDE) database, which promotes voluntary reporting of complications. The Panel has reviewed this statement and the results of this meta–analysis. Based on this review, the Panel has reached the following conclusions:

1. In this meta–analysis, the midurethral slings had an efficacy comparable to autologous slings in the surgical treatment of SUI.

2. Several "versions" of the midurethral sling procedures do not have similar long–term efficacy data.

3. There are complications that may occur that are unique to specific mesh materials; however, these complications appear to be rare. Intraoperative use of cystoscopy can be performed to minimize the risk of urinary tract injury or erosion.

4. The midurethral sling is an alternative in the management of SUI. The incidence and implications of these complications along with the more rapid recovery and more efficient return to normal voiding after surgery should be discussed with patients before surgery.

Injectable Agents

Injectable agents may provide immediate relief for some patients and are an option for patients who do not wish to undergo more invasive surgery and who understand that both efficacy and duration are inferior to surgery. Other possible indications for the use of injectable agents include patients who are elderly, those who are at high anesthetic risk or those willing to accept an improvement in their incontinence without necessarily achieving dryness.

For this analysis, injectable agents were subdivided into collagen (bovine gluteraldehyde cross–linked) and other nondegradable synthetic agents. The literature reviewed for this guideline offered minimal new data, with sufficient data available for an analysis of only collagen. The anticipated efficacy for patients treated with collagen without concomitant prolapse treatment declined over time, from 48% at 12 to 23 months to 32% at 24 to 47 months (Table 1). The estimated rates of de novo and unspecified urge incontinence as well as the rates of complications were low.

Very limited information is available for the other injectable agents with the exception of the multicenter trials that won approval for these agents by the U.S. FDA. These include carbon– coated zirconium beads in beta–glucan gel22 and calcium hydroxylapatite.23 Data regarding newer agents under FDA review or not yet in the literature were not included. There were limited data with which to assess the long–term safety and efficacy of injectable agents. These agents are an option for women who require or prefer a minimally invasive procedure under local anesthesia.

Artificial Urinary Sphincters

In the U.S., use of the AUS is generally restricted to children with nonfunctioning urethras (i.e., those with spina bifida), in adults with nonfunctioning urethras secondary to trauma to the nerves of the pelvis such as following automobile accidents or in male adults with postprostatectomy incontinence. Data on use of the AUS in the index patient are limited. It is occasionally used in a patient with severe intrinsic sphincteric deficiency who has failed other surgical procedures, or patients with significant SUI and poor bladder contractility such as those with diabetes or back injury. Although limited, available data on the AUS in over a decade of use demonstrate that it can be a valuable therapy with a high degree of effectiveness. Erosion, infection and device malfunction are potential complications. Based on the only recent study on complications, an anticipated erosion/extrusion rate was computed to be 28%.24 With respect to the index patient, the AUS might be useful in the Valsalva–voiding woman who must abdominally strain to empty the bladder. When the cuff is opened for voiding, the AUS is likely nonobstructive to the bladder in contrast to slings where straining may cause obstruction to the flow of urine. The Panel feels that the role of the AUS is limited.

Treatment Guidelines for the Index Patient

The Panel updated existing guideline statements and developed new statements. Amendments to 1997 Standards, Recommendations and Options are indicated (words that are in italics denote changes from the 1997 guideline document to improve clarity).

Standard: The patient should be counseled regarding the surgical and nonsurgical options including both benefits and risks. Choice of the procedure should be made as a collaborative effort between the surgeon and patient and should consider both patient preferences and the surgeon's experience and judgment.

[Based on Panel consensus]

Standard: Patients with urge incontinence without stress incontinence should not be offered a surgical procedure for stress incontinence. The index patient has stress urinary incontinence with or without prolapse. The use of a prophylactic anti–incontinence procedure in the patient with occult incontinence with high grade prolapse is not the guideline index patient and the panel does not have an opinion about prophylactic incontinence surgery.

[Based on Panel consensus]

Recommendation: Synthetic sling surgery is contraindicated in stress incontinent patients with a concurrent urethrovaginal fistula, urethral erosion, intraoperative urethral injury and/or urethral diverticulum.

[Based on Panel consensus]

Although there is no peer–reviewed literature that specifically evaluates these uncommon conditions, the Panel believes that using synthetic material in these circumstances may place the patient at higher risk for subsequent urethral erosion, vaginal extrusion, urethrovaginal fistula and foreign body granuloma formation. In such patients, the Panel believes that autologous fascial and alternative biologic slings are an option in the treatment of concomitant stress incontinence. The decision to use these materials should be based on the judgment of the surgeon and made in the best interests of the patient.

Standard: Intraoperative cystourethroscopy should be performed in all patients undergoing sling surgery.

[Based on Panel consensus]

For detection of potential intraoperative complications, the bladder and urethra should be inspected either with a rigid or flexible cystoscope prior to the conclusion of the procedure. A short beak rigid cystoscope or flexible fiberoptic cystoscope provides optimal visualization of the female urethra.

Option: The five major types of procedures (injectables, laparoscopic suspensions, midurethral slings, pubovaginal slings and retropubic suspensions), although not equivalent, may be considered for the index patient.

[Based on Panel consensus]

Newer techniques and materials for the surgical treatment of stress incontinence such as midurethral synthetic slings have been developed. For the index patient, the Panel believes that these techniques, materials and accompanying physician expertise and experience offer a number of advantages that include shorter operative time, shorter recovery time and less short–term morbidity; however, urethral erosion and vaginal extrusion of the synthetic material may occur, which can be very difficult to treat. In addition, perforation of bowel and blood vessels, which pose a life–threatening risk, may result from this procedure. Longer term follow–up is needed before any definitive statements regarding the long–term efficacy and life–long risk of erosion with these procedures can be made.

Option: The artificial urinary sphincter may be indicated in certain circumstances.

[Based on evidence and Panel opinion]

The Panel considers the use of the AUS in the index patient as an option, with a role limited to patients not amenable to treatment with other procedures.

Option: Stress incontinence procedures may be considered for patients with mixed incontinence with a significant stress incontinence component.

[Based on review of the data and Panel consensus]

Ample support exists for the role of surgery in mixed incontinence25 The meta–analysis estimate of postoperative urge incontinence was 14% from data from 186 patients (CI: 6% – 25%) with pre–existing urge incontinence when treated with open retropubic suspensions while others have reported disparate outcomes.26

Recommendation: Surgical procedures for SUI and prolapse may be safely performed concomitantly in appropriately selected women. Tensioning of any sling should not be performed until prolapse surgery is completed.

[Based on Panel consensus]

Recommendations for Future Research and Reporting

Recommendations to Editors and Reviewers

Although more than a decade has passed since the recommendations for improving the quality of data from clinical trials and studies were proposed by Leach et al.,4 very little progress has been made by editors and reviewers in instituting these recommendations.27 Furthermore, the FDA has not altered the approval process as discussed below. Thus, again, the Panel members were extremely disappointed in data available for meta–analysis. In addition to the specific data outlined by Leach et al.4 in the original Panel report, editors and their reviewers should require:

A minimum follow–up of at least 12 months of all surgically treated patients for reporting of efficacy data

For adverse event data, complications should be categorized as occurring intraoperatively or postoperatively. It is essential to report the following adverse event data:

The profession at large and the individual physician should insure the safety and efficacy of any new device or sling. If safety and efficacy has not been shown with reasonable certainty, the new treatment should only be performed as part of clinical research studies and/or with informed consent recognizing that safety and/or efficacy has not been demonstrated.

Transobturator Tape Procedures

As previously discussed, modifications to the pubovaginal sling since the 1997 guideline include development of two minimally invasive procedures for the surgical treatment of SUI: the tension–free vaginal tape procedure introduced in 1996,28 and the transobturator technique, introduced in 2001.29–31

In the development of this guideline, the Panel established June 2005 as a cut–off date for literature review. At that time, the transobturator was a novel procedure with limited information available in the published literature, precluding inclusion of the procedure in the data analyses. Since that deadline, numerous articles have been published in the peer–reviewed literature regarding the transobturator procedure. The Panel is very aware of the importance of the transobturator procedure in the current practice of urology and urogynecology.

Table 1. Cured/dry analysis – No concurrent prolapse treatment*

12–23 months 24–47 months

≥48 months

G/P

Median%
(CI 2.5% – 97.5%)

G/P

Median %
(CI 2.5% – 97.5%)

G/P

Median %
(CI 2.5% – 97.5%)

Suspensions
All Open Retropubic 15/1085 82% (74 – 87)% 13/803 76% (68 – 82)% 17/1259 73% (64 – 77)%
Burch 14/1070 81% (73 – 87)% 12/775 76% (68 – 83)% 13/1065 73% (65 – 80)%
Laparoscopic 9/368 69% (52 – 84)% 4/172 74% (61 – 85)%
Slings
Autologous fascial
without bone anchors 4/342 90% (76 – 98)% 6/232 81% (72 – 88)% 4/368 82% (67 – 93)%
vaginal wall slings w/without bone anchors 1/39 79% (65 – 90)%

1/29

96% (85 – 100)%
vaginal wall slings with bone anchors 1/58 79% (68 – 88)%
Cadaveric without bone anchors 1/104 74% (65 – 82)% 2/71 80% (43 – 98)%
Synthetic at bladder neck
with bone anchors 2/34 88% (71 – 97)%

1/27

92% (78 – 98)%
without bone anchors 9/349 73% (64 – 80)%
Synthetic at midurethra 14/1215 84% (78 – 89)% 7/483 81% (72 – 88)% 3/199 84% (77 – 89)%
Injectables
Collagen 7/340 48% (41 – 55)% 4/210 32% (24 – 42)%

1/40

30% (18 – 45)%

G=number of groups/arms in analysis; P=number of patients in analysis

*By any evaluation method, including subjective and objective

Table 2. Cured/dry analysis: ANY patient in the group/arm receiving concurrent prolapse treatment*

12–23 months 24–47 months

≥48 months

G/P

Median%
(CI 2.5% – 97.5%)

G/P

Median %
(CI 2.5% – 97.5%)

G/P

Median %
(CI 2.5% – 97.5%)

Suspensions
All Open Retropubic 9/517 88% (83 – 92)% 9/403 83% (75 – 90)% 13/1072 67% (56 – 76)%
Burch 9/517 88% (83 – 92)% 7/333 85% (75 – 93)% 12/954 65% (53 – 74)%
Laparoscopic 12/564 88% (85 – 91)% 7/359 83% (73 – 91)% 1/34 88% (74 – 96)%
Slings
Autologous fascial
without bone anchors 3/78 92% (82 – 97)% 1/80 85% (76 – 92)%
vaginal wall slings w/without bone anchors

1/20

70% (48 – 86)%

2/60

89% (64 – 99)%

1/82

95% (89 – 98)%

vaginal wall slings with bone anchors, suprapubic

1/19

99% (88 – 100)%

1/9

87% (59 – 99)%

Cadaveric
with bone anchors –transvaginal 1/234 82% (77 – 86)%
without bone anchors 3/133 58% (36 – 78)% 2/92 64% (21 – 95)% 1/13 31% (11 – 58)%
Homologous dermis without bone anchors 1/19 89% (70 – 98)%
Synthetic at bladder neck
with bone anchors–suprapubic 1/49 85% (74 – 93)%
with bone anchors– transvaginal 1/32 81% (65 – 92)%
without bone anchors 1/20 94% (79 – 99)% 3/184 75% (56 – 90)% 3/182 73% (62 – 82)%
Synthetic at midurethra 14/1089 85% (80 – 89)% 11/881 87% (81 – 91)% 2/101 76% (64 – 85)%
Other Sling 1/126 92% (86 – 96)%

G=number of groups/arms in analysis; P=number of patients in analysis

*By any evaluation method, including subjective and objective; includes groups/arms in which ANY patient had a concurrent prolapse treatment.

Table 3. Urge incontinence outcomes at 12–23 months

No Prolapse Treatment

De Novo Pre–Existing Unspecified

G/P

Median%
(CI 2.5% – 97.5%)

G/P

Median %
(CI 2.5% – 97.5%)

G/P

Median %
(CI 2.5% – 97.5%)

Suspensions
All Open Retropubic 10/713 8% (5 – 12)% 5/186 14% (6 – 25)% 4/305 41% (30 – 54)%
Burch 9/695 8% (5 – 11)% 3/108 17% (4 – 40)% 4/305 41% (30 – 54)%
Laparoscopic 2/112 5% (1 – 14)% 2/100 6% (1 – 14)%
Slings
Autologous fascial
without bone anchors 4/329 9% (6 – 13)% 4/358 33% (28 – 40)%
vaginal wall slings w/without bone anchors 1/13 9% (1 – 31)%
vaginal wall slings with bone anchors
Cadaveric without bone anchors 1/25 28% (13 – 47)% 1/38 21% (10 – 36)%
Synthetic at bladder neck with bone anchors

1/6

96% (67 – 100)%
Synthetic at bladder neck without bone anchors 4/132 12% (6 – 20)% 1/24 17% (6 – 35)%
Synthetic at midurethra 7/323 6% (3 – 10)% 1/25 44% (26 – 63)% 2/532 22% (3 – 58)%
Other Sling
Injectables
Collagen 1/337 13% (10 – 17)% 1/50 8% (3 – 18)%

Any Prolapse Treatment*

Suspensions
All Open Retropubic 10/457 14% (8 – 21)% 2/143 22% (4 – 56)% 2/256 13% (7 – 22)%
Burch 9/417 14% (8 – 22)% 1/25 48% (30 – 67)% 2/256 13% (7 – 22)%
Laparoscopic 5/344 11% (6 – 17)% 1/32 4% (0 – 14)%
Slings
Autologous fascial
without bone anchors 2/97 10% (4 – 19)%
vaginal wall slings w/without bone anchors 3/65 13% (2 – 36)% 2/15 47% (21 – 75)%
vaginal wall slings with bone anchors suprapubic

1/9

13% (1 – 41)%
Cadaveric with bone anchors – transvaginal 1/238 6% (3 – 9)%
Homologous tissue (dermis) without bone anchors

1/5

22% (2 – 63)%
Synthetic at bladder neck without bone anchors 4/150 15% (5 – 31)% 3/119 29% (16 – 46)%
Synthetic at midurethra 11/805 11% (7 – 16)% 5/107 52% (38 – 66)% 2/174 9% (1 – 38)%

G=number of groups/arms in analysis; P=number of patients in analysis

**By any evaluation method, including subjective and objective; includes groups/arms in which ANY patient had a concurrent prolapse treatment.

Table 4. Retention*

No prolapse treatment Any prolapse treatment**

G/P

Median%
(CI 2.5%– 97.5%)

G/P

Median %
(CI 2.5% – 97.5%)

Suspensions
All Open Retropubic 8/619 4% (1 – 8)% 13/851 1% (1 – 3)%
Burch 5/347 3% (1 – 7)% 10/710 1% (1 – 3)%
Laparoscopic 5/188 4% (1 – 8)% 11/482 2% (1 – 4)%
Slings
Autologous fascial
without bone anchors 8/480 8% (4 – 15)% 3/301 5% (2 – 11)%
vaginal wall slings w/without bone anchors 2/68 2% (0 – 8)% 3/142 5% (1 – 17)%
Suprapubic 1/25 1% (0 – 9)%
Cadaveric without bone anchors 1/26 1% (0 – 10)%
Synthetic at bladder neck
with bone anchors – suprapubic 1/49 4% (1 – 12)%
with bone anchors – transvaginal 2/99 1% (0 – 6)%
without bone anchors 4/360 9% (5 – 15)% 7/422 10% (5 – 18)%
Synthetic at midurethra 17/2119 3% (2 – 4)% 11/1107 3% (2 – 5)%
Injectables
Collagen 2/104 1% (0 – 5)%

G=number of groups/arms in analysis; P=number of patients in analysis

* Duration greater than 28 days or requiring intervention

**By any evaluation method, including subjective and objective; includes groups/arms in which ANY patient had a concurrent prolapse treatment.

References

1. Luber KM: The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004; 6: S3.

2. Hampel C, Weinhold D, Benken N et al: Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997; 50: 4.

3. Hampel C, Artibani W, Espuña Pons M et al: Understanding the burden of stress urinary incontinence in Europe: a qualitative review of the literature. Eur Urol 2004; 46: 15.

4. Leach GE, Dmochowski RR, Appell RA et al: Female Stress Urinary Incontinence Clinical Guidelines Panel summary report on surgical management of female stress urinary incontinence. The American Urological Association. J Urol 1997; 158: 875.

5. Abrams P, Cardozo L, Fall M et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub–committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167.

6. Weber AM, Abrams P, Brubaker L et al: The Standardization of Terminology for Researchers in Female Pelvic Floor Disorders. Int Urogynecol J 2001; 12: 178.

7. Eddy DM. (1992). A manual for assessing health practices & designing practice policies: the explicit approach. Philadelphia (AP): American College of Physicians.1992; 55.

8. Eddy DM: The confidence profile method: a Bayesian method for assessing health technologies. Oper Res 1989; 37: 210.

9. Eddy DM, Hasselblad V and Schachter R: A Bayesian method for synthesizing evidence: the confidence profile method. Int J Technol Assess Health Care 1990; 6: 31.

10. Handa VL, Jensen JK, Germain MM et al: Banked human fascia lata for the suburethral sling procedure: a preliminary report. Obstet Gynecol 1996; 88: 1045.

11. Elliott DS and Boone TB: Is fascia lata allograft material trustworthy for pubovaginal sling repair? Urology 2000; 56: 772.

12. Flynn BJ and Yap WT: Pubovaginal sling using allograft fascia lata versus autograft fascia for all types of stress urinary incontinence: 2–year minimum followup. J Urol 2002; 167: 608.

13. Fitzgerald MP, Mollenhauer J, Bitterman P et al: Functional failure of fascia lata allografts. Am J Obstet & Gynecol 1999; 181: 1339.

14. Huang Y, Lin A, Chen K et al: High failure rate using allograft fascia lata in pubovaginal sling surgery for female stress urinary incontinence. Urology 2001; 58: 943.

15. Carbone JM, Kavaler E, Hu JC et al: Pubovaginal sling using cadaveric fascia and bone anchors: disappointing early results. J Urol 2001; 165: 1605.

16. Fitzgerald MP, Mollenhauer J and Brubaker L: Failure of allograft suburethral slings. BJU Int 1999; 84: 785.

17. Owens DC and Winters JC: Pubovaginal sling using Duraderm graft: intermediate follow–up and patient satisfaction. Neurourol Urodyn 2004; 23: 115.

18. O'Reilly KJ and Govier FE: Intermediate term failure of pubovaginal slings using cadaveric fascia lata: a case series. J Urol 2002; 167: 1356.

19. Hathaway JK and Choe JM: Intact Genetic material is present in commercially processed cadaver allografts used for pubovaginal slings. J Urol 2002; 168: 1040.

20. Clemens JQ, DeLancey JO, Faerber GJ et al: Urinary tract erosions after synthetic pubovaginal slings: diagnosis and management strategy. Urology 2000; 56: 589.

21. Chung SV, Franks M, Smith CP et al: Technique of combined pubovaginal sling and cystocele repair using a single piece of cadaveric dermal graft. Urology 2002; 59: 538.

22. Lightner, D., Calvosa, C., Andersen, R., et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double–blind study of Durasphere. Urol, 58:12–15, 2001

23. Mayer RD, Dmochowski RR, Appell RA et al: Multicenter prospective randomized 52– week trial of calcium hydroxyl apatite versus bovine dermal collagen for treatment of stress urinary incontinence. J Urol 2007; 69: 876.

24. Costa, P., Motett, N., Rabut, B., et al. The use of an artificial urinary sphincter in women with type III incontinence and a negative Marshall test. JUrol 165: 1172–6, 2001

25. Chou EC, Flisser AJ, Panappoulos G et al: Effective treatment for mixed urinary incontinence with a pubovaginal sling. J Urol 2003; 170: 494.

26. Anger JT and Rodriguez LV: Mixed incontinence: stressing about urge. Curr Urol Rep 2004; 5: 427.

27. Rovner ES, Wright CJ and Messer H: Adherence to the 1997 AUA Guidelines for the surgical treatment of stress urinary incontinence. Urology 2008; 71: 239.

28. Ulmsten U, Henriksson L, Johnson P et al: An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1996; 7: 81.

29. Delorme E: Transobturator urethral suspension: mini–invasive procedure in the treatment of stress urinary incontinence in women. Prog Urol 2001; 11: 1306–13.

30. Delorme E, Droupy S, de Tayrac Ret al: Transobturator tape (Uratape). A new minimally invasive method in the treatment of urinary incontinence in women. Prog Urol 2003; 13: 656–9.

31. Delorme E, Droupy S, de Tayrac Ret al: Transobturator tape (Uratape): a new minimally–invasive procedure to treat female urinary incontinence. Eur Urol 2003; 45: 203–7.

Abbreviations and Acronyms

AUA American Urological Association
AUS artificial urinary sphincter
CI confidence interval
etc. et cetera; and the rest
et al. and others
FDA Food and Drug Administration
G groups
i.e. that is
P patients
PGC Practice Guidelines Committee
RCT randomized controlled trial
sine qua non an essential or indispensable element or condition
SUI stress urinary incontinence
U.S. United States
w/ with

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT